Related Experiment Videos
Omeprazole and aryl hydrocarbon hydroxylases: should we be worried?
J C Kolars1, D K Turgeon, P B Watkins
1University of Michigan Medical Center, Ann Arbor 48109.
Hepatology (Baltimore, Md.)
|January 1, 1991
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials.
Clinical pharmacology and therapeutics·2017
Systems pharmacology modeling of drug-induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters.
Clinical pharmacology and therapeutics·2017
Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management.
Clinical pharmacology and therapeutics·2016
Blood gene expression profiling of an early acetaminophen response.
The pharmacogenomics journal·2016
Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury.
CPT: pharmacometrics & systems pharmacology·2016
Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen.
Clinical pharmacology and therapeutics·2015
Hepatocyte hnRNPK preserves mitochondrial integrity to restrain liver injury and fibrosis.
Hepatology (Baltimore, Md.)·2026
Liver-on-a-Chip: Applications for clinical modeling of liver disease using microscale systems.
Hepatology (Baltimore, Md.)·2026
BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma.
Hepatology (Baltimore, Md.)·2026